USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC KIDNEY DISEASE – CLINICAL EXPERIENCE OF BULGARIAN PEDIATRIC GROUP [PDF]
Journal of IMAB, 2017 Darbepoetin alfa (DA) is indicated for treatment of symptomatic anemia related to chronic kidney disease (CKD) in adult and pediatric patients. In comparison with the recombinant human erythropoietin (rHuEpo), darbepoetin alfa has two additional ...
Maria Gaydarova +3 more
doaj +1 more source
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. [PDF]
, 2002 In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g x kg(-1) x wk(-1) or to a control group receiving epoetin alfa at an initial dose of 150 U x kg(-1) three times weekly.
Armstrong, S +10 more
core +2 more sources
Journal of the Formosan Medical Association, 2008 Darbepoetin alfa can be administered less frequently than recombinant human erythropoietin (r-HuEPO) for the treatment of anemia in chronic renal failure (CRF) patients.
Wen-Yi Li +4 more
doaj +1 more source
Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy. [PDF]
PLoS ONE, 2010 BackgroundErythropoiesis stimulating agents (ESAs) are widely used to treat anaemia but concerns exist about their potential to promote pathological angiogenesis in some clinical scenarios.
Carmel M McVicar +9 more
doaj +1 more source
Cloning and expression of codon-optimized recombinant darbepoetin alfa in Leishmania tarentolae T7-TR [PDF]
, 2016 Darbepoetin alfa is an engineered and hyperglycosylated analog of recombinant human erythropoietin (EPO) which is used as a drug in treating anemia in patients with chronic kidney failure and cancer.
Fard-Esfahani, P. +8 more
core +1 more source
Purification and Characterization of Recombinant Darbepoetin Alfa from Leishmania tarentolae [PDF]
, 2016 Darbepoetin alfa is a biopharmaceutical glycoprotein that stimulates erythropoiesis and is used to treat anemia, which associated with renal failure and cancer chemotherapy.
Ansari, J. +8 more
core +1 more source
Indian Journal of Transplantation, 2018 Introduction: The present study compared the efficacy, safety, and immunogenicity of the biosimilar darbepoetin alfa to the reference innovator darbepoetin alfa in the treatment of anemia in chronic kidney disease (CKD) patients.
Prasad Apsangikar +4 more
doaj +1 more source
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. [PDF]
, 2019 PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
Bohlius, Julia +12 more
core +3 more sources
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer : randomized clinical trial [PDF]
, 2013 BACKGROUND: The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin ...
Bois, Andreas du +13 more
core +1 more source
The effect of darbepoetin alfa on the glomerulus of new-born mice with intrauterine growth restriction [PDF]
Srpski Arhiv za Celokupno LekarstvoIntroduction/Objective. Intrauterine growth restriction is a condition in which a fetus is not able to achieve its genetic potential for growth. It has been linked with diseases of adulthood, such as hypertension, insulin-independent diabetes mellitus ...
Milojković Milica +2 more
doaj +1 more source